Alpha-9 Oncology Inc. is a clinical stage radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects.
Market
Oncology
Location
Boston,
MA,
USA
Coinvestors
A16z, abrdn, Ascenta Capital, BVF Partners, Delos Capital, Digitalis Ventures, Frazier Life Sciences, General Catalyst Partners, Janus Henderson Investors, Lightspeed Venture Partners, Longitude Capital, Lumira Ventures, Nextech Invest, RA Capital Management, Samsara BioCapital